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A B S T R A C T
In order to investigate the impact of Pneumocystis
carinii infection in southern Spain following the
introduction of highly active anti-retroviral ther-
apy (HAART), all cases of pneumocystosis be-
tween 1998 and 1999 were identified from data
compiled by the national surveillance system. In
total, 498 cases of pneumocystosis were recorded,
of which 87% involved HIV-positive patients. The
mean age, length of hospital stay and mortality
were higher for HIV-negative patients. There
was a higher number of cases in winter. Des-
pite HAART implementation, pneumocystosis
remains a significant health problem for both
HIV-positive and HIV-negative patients.
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Pneumonia caused by Pneumocystis carinii (PCP)
is one of the most frequent and serious oppor-
tunistic infections, and a leading cause of death,
for patients with AIDS. During the 1990s, advan-
ces in the treatment of HIV, principally highly
active anti-retroviral therapy (HAART), have
reduced the frequency of PCP and other compli-
cations. Nevertheless, P. carinii remains a leading
cause of opportunistic infection, morbidity and
mortality for this group of patients [1]. Interest in
P. carinii infection now extends beyond AIDS
patients, since it is a frequent opportunistic
pulmonary infection in immunosuppressed HIV-
negative patients [2–4] and can also affect
individuals with no apparent immunosuppres-
sion [5,6]. The organism has also been associated
with certain autoimmune disorders, such as anti-
cardiolipin antibodies and Goodpasture syn-
dromes [7,8]. The aim of this study was to
investigate the extent of P. carinii infection in the
population of southern Spain following the intro-
duction of HAART for AIDS control.
The patients studied were identified through a
search of data compiled by the Spanish national
surveillance system for hospital data (Conjunto
Minimo Basico de Datos), managed by the Span-
ish Ministry of Health [9]. This system uses
clinical codes from The International Classification
of Diseases, 9th Revision, Clinical Modification: ICD-
9-CM [10], and covers all 32 public hospitals in
Andalusia, an autonomous region with a popula-
tion of 7 314 644 in southern Spain. Compulsory
health insurance covers an estimated 99.5% of the
Spanish population [9]. The discharge abstracts of
Conjunto Minimo Basico de Datos include patient
demography, physician-reported diagnoses (up
to ten), major procedures and disposition. Data
were collected for all hospital admissions of
patients with pneumocystosis in Andalusian pub-
lic hospitals from 1998 (2 years after the intro-
duction of HAART in Spain) to 1999. The
chi-square test with Yates’s correction or Fisher’s
exact test was used to assess differences between
proportions. The Mann–Whitney U-test was used
to assess differences in the study variables.
Statistical analyses were performed with SPSS
software v. 10.0 (SPSS Inc., Chicago, IL, USA) and
the EpiInfo program v. 6.5 (Centers for Disease
Control and Prevention, Atlanta, GA, USA).
During the study period, 498 cases of pneumo-
cystosis were recorded in Andalusia in the 32
public hospitals (273 in 1998 and 225 in 1999),
with an annual average incidence of 3.4
cases ⁄ 100 000 population, and an associated total
hospitalisation of 10 201 days. The mean age of
the patients was 37.7 ± 11.9 years, and 79% of the
patients were male (Table 1).
Of the total PCP cases analysed, 434 (87%)
patients were HIV-positive and 64 (13%) were
HIV-negative. Patients without HIV had different
predisposing factors, such as haematological
malignancies (15), organ transplants (11), solid
tumours (six) and connective tissue diseases
(two). In five cases, the only underlying condition
was an age of > 75 years. The remaining 25 (39%)
patients had a wide miscellany of risk factors,
varying from primary immunodeficiency to alco-
holism or malnutrition.
Table 1. Distribution of pneumocystosis cases by age,
gender and HIV status
HIV status Age-groups (years)
Gender
TotalMale Female
Positive < 11 2 1 3
11–20 1 2 3
21–30 56 22 78
31–40 229 43 272
41–50 42 8 50
51–60 19 2 21
61–70 1 1 2
71–80 3 0 3
> 80 1 1 2
Total 354 80 434
Negative < 11 0 1 1
11–20 4 3 7
21–30 3 3 6
31–40 9 5 14
41–50 6 2 8
51–60 5 2 7
61–70 8 3 11
71–80 3 4 7
> 80 2 1 3
Total 40 24 64
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Fig. 1. Seasonal distribution of cases of pneumocystosis.
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Compared to HIV-positive patients, HIV-negat-
ive patients with pneumocystosis had a higher
mean age (46.6 ± 20.9 years vs. 35.9 ± 9.1 years;
p 0.0001), a longer average length of hospita-
lisation (26.4 ± 26.1 days vs. 19.6 ± 14.5 days;
p 0.021), and greater associated mortality (23.1%
vs. 11.8%; p 0.012).
Cases of pneumocystosis were recorded in each
month of the year (Fig. 1), and a seasonal distri-
bution was observed, with a higher number of
cases (30.5%) in winter, compared with spring
(23.9%), summer (23.7%) and autumn (21.9%)
(p 0.0035).
For several reasons, PCP remains a frequent
and severe problem for AIDS patients in southern
Spain, with a mortality rate of 11.8%. First, PCP is
sometimes the initial AIDS-defining event in
patients with previously unrecognised HIV infec-
tion; indeed, PCP is the most frequent initial
AIDS-defining event in Europe [11]. Second, it is
possible that some patients with HIV infection did
not receive or continue anti-retroviral treatment,
or had poor compliance, which leads to a poor
therapeutic response and the development of
resistance [12]. The present data indicated that
13% of the patients were HIV-negative, thereby
confirming that pneumocystosis is a disease that
extends beyond AIDS patients [13]. As shown
previously [14], the most frequent underlying
conditions in these patients were haematological
malignancies, solid tumours and organ trans-
plants. In this population, PCP was more severe
and affected elderly patients who had mean
longer hospitalisation periods. The mortality rate
in this group duplicated that of AIDS patients, as
reported previously [15]. This situation could be a
consequence of the underlying disorders, or of
delayed PCP identification and initiation of ther-
apy, since physicians treating non-AIDS patients
are not focusing on this disease [16].
Seasonal variations among PCP cases have
been evaluated in a few reports [17,18], but no
clear pattern of temporal distribution has
emerged, perhaps because of small sample sizes
[19,20]. For the first time, the present study
demonstrated seasonal variation in P. carinii
infections in humans, with a higher incidence of
PCP in the colder winter months in a broad
population of patients. This seasonal pattern
supports the hypothesis of air-borne P. carinii
transmission, and is consistent with infection
caused by P. carinii during the colder months
with a short incubation period, or with other
upper respiratory tract diseases predisposing to
subsequent PCP.
Overall, the results of this study demonstra-
ted that, despite the implementation of HAART,
PCP continues to be a significant health prob-
lem, with a relatively high prevalence and
mortality rate, for both HIV-positive and HIV-
negative patients.
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A B S T R A C T
Treatment of severe acute respiratory syndrome
(SARS) is experimental, and the effectiveness of
ribavirin–steroid therapy is unclear. Forty SARS
patients with progressive disease after ribavirin
treatment and 1.5 g of pulsed methylprednisolone
were given either convalescent plasma (n = 19) or
further pulsed methylprednisolone (n = 21) in a
retrospective non-randomised study. Good clin-
ical outcome was defined as discharge by day 22
following the onset of symptoms. Convalescent
plasma was obtained from recovered patients
after informed consent. Patients in the plasma
group had a shorter hospital stay (p 0.001) and
lower mortality (p 0.049) than the comparator
group. No immediate adverse effects were
observed following plasma infusion.
Keywords Convalescent plasma, methylpredniso-
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In Hong Kong, the first major outbreak of severe
acute respiratory syndrome (SARS) commenced
on 10 March 2003 in the Prince of Wales Hospital,
with > 130 persons becoming infected [1]. This
highly infectious respiratory illness was caused
by a novel coronavirus [2,3]. Treatment was
mainly empirical and, in the Prince of Wales
Hospital, ribavirin and steroids were used as first-
line treatment to suppress viral replication and
minimise autoimmune pneumonitis. In c. 74% of
the patients, the ribavirin–steroid combination
was associated with recovery [4]. However, there
was great debate as to whether ribavirin was
effective against coronavirus, as well as concern
about the side effects of high-dose steroids.
Patients with persistent fever, radiographic pro-
gression and hypoxaemia, despite receiving 1.5 g
of methylprednisolone, responded poorly to fur-
ther courses of high-dose steroids, and an alter-
native therapy was needed. It was postulated that
convalescent plasma from recovered SARS
patients would carry antibodies against the
coronavirus and might suppress viraemia.
A retrospective comparison study was per-
formed on SARS patients admitted between
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